Subtle Medical raises $33M Series C led by Morgan Stanley Expansion Capital
What's the deal? Subtle Medical, a Menlo Park-based maker of AI-powered medical imaging software, has raised $33M in growth capital led by Morgan Stanley Expansion CapitalDealroom has a profile for this one. Try Dealroom →. The Series C round included participation from Korea's Shinhan Venture InvestmentDealroom has a profile for this one. Try Dealroom → and existing backers Fusion FundDealroom has a profile for this one. Try Dealroom →, EnvisionXDealroom has a profile for this one. Try Dealroom →, BRVDealroom has a profile for this one. Try Dealroom →, and Samsung VenturesDealroom has a profile for this one. Try Dealroom →, bringing total capital raised to $86M.
Alongside the funding, the company appointed Ohad Arazi as chief executive officer. Arazi previously held CEO and leadership roles at Change Healthcare, Zebra Medical Vision, and Clarius Mobile HealthDealroom has a profile for this one. Try Dealroom →.
Co-founder Enhao Gong, the former CEO, has moved to chief science officer, where he will lead the scientific roadmap and support partnerships in China.
Why now? Medical imaging remains a bottleneck across health systems. Exams can be lengthy and uncomfortable — especially for paediatric, elderly, and critically ill patients — while longer scan times reduce image quality, delay diagnoses, and limit scanner capacity.
Subtle Medical's software improves image quality and accelerates scans on existing hardware, supporting up to an 80% reduction in scan time. It is deployed on more than 1,300 scanners globally, with customers including Mount SinaiDealroom has a profile for this one. Try Dealroom →, RadNetDealroom has a profile for this one. Try Dealroom →, and Radiology Partners.
The company plans to use the new capital to accelerate product development, expand global commercial adoption, and scale its vendor-neutral AI platform across MRI, PET, and CT workflows.
What could go wrong? Subtle competes with OEM-native AI tools built into scanners from major manufacturers — companies with deep pockets and existing customer relationships. Convincing health systems to adopt a third-party layer on top of their existing equipment requires trust, regulatory clearance, and proven ROI at scale.
The company also faces the classic challenge of any vendor-neutral platform: maintaining compatibility across a fragmented hardware landscape as scanner technology evolves.
The signal: Subtle Medical's "breakout" growth stage, per Dealroom, aligns with a wider shift in healthcare AI investment away from single-purpose diagnostic tools and toward platform infrastructure that sits across existing hardware. The involvement of Morgan Stanley Expansion Capital — a growth-stage investment fund rather than an early-stage healthtech specialist — suggests institutional investors see vendor-neutral imaging AI as a category ready to scale commercially, not just clinically. Participation from Korea's Shinhan Venture Investment alongside Samsung Ventures also underscores growing Asia-Pacific appetite for cross-border medtech platforms.
Read more: PR Newswire
